NASDAQ:EOLS - Evolus Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evolus Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.69 +0.35 (+3.75 %) (As of 02/18/2020 08:00 AM ET) Add Compare Today's Range$9.20Now: $9.69▼$9.7150-Day Range$9.34MA: $10.58▼$12.2152-Week Range$9.20Now: $9.69▼$29.50Volume670,986 shsAverage Volume621,305 shsMarket Capitalization$323.84 millionP/E RatioN/ADividend YieldN/ABeta4.3 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EOLS Previous Symbol CUSIPN/A CIK1570562 Webhttp://www.evolus.com/ Phone949-284-4555Debt Debt-to-Equity Ratio4.53 Current Ratio3.66 Quick Ratio3.28Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book3.14Profitability EPS (Most Recent Fiscal Year)($1.57) Net Income$-46,870,000.00 Net MarginsN/A Return on Equity-188.09% Return on Assets-52.68%Miscellaneous Employees70 Outstanding Shares33,420,000Market Cap$323.84 million Next Earnings Date2/25/2020 (Confirmed) OptionableOptionable Receive EOLS News and Ratings via Email Sign-up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EOLS Rates by TradingView Evolus (NASDAQ:EOLS) Frequently Asked Questions What is Evolus' stock symbol? Evolus trades on the NASDAQ under the ticker symbol "EOLS." How were Evolus' earnings last quarter? Evolus Inc (NASDAQ:EOLS) announced its quarterly earnings results on Monday, November, 4th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.33) by $0.55. The business earned $13.17 million during the quarter, compared to the consensus estimate of $5.18 million. View Evolus' Earnings History. When is Evolus' next earnings date? Evolus is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Evolus. How can I listen to Evolus' earnings call? Evolus will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. What guidance has Evolus issued on next quarter's earnings? Evolus updated its FY 2019 Pre-Market earnings guidance on Thursday, January, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $34-35 million, compared to the consensus revenue estimate of $31.8 million. What price target have analysts set for EOLS? 10 brokers have issued twelve-month price objectives for Evolus' stock. Their forecasts range from $13.00 to $37.00. On average, they anticipate Evolus' stock price to reach $26.40 in the next twelve months. This suggests a possible upside of 172.4% from the stock's current price. View Analyst Price Targets for Evolus. What is the consensus analysts' recommendation for Evolus? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evolus. What are Wall Street analysts saying about Evolus stock? Here are some recent quotes from research analysts about Evolus stock: 1. According to Zacks Investment Research, "Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California. " (10/15/2019) 2. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution and ahead of what we expect to be a better-than-expected launch of Jeuveau, we are reiterating our OW rating and 12-month price target of $35. We think Jeuveau’s value proposition is underappreciated and that it will pick up more market share than anticipated. Therefore, the U.S. and other launches should drive EOLS’s stock higher, in our view." (4/30/2019) 3. HC Wainwright analysts commented, "We think investors understand that Evolus will offer discounts and rebates off the list price, but we have sensed continued confusion over what Evolus is trying to accomplish by setting its list price where it did. While inconsequential for our financial model, Evolus’ move reinforces a couple important elements of the company’s commercial strategy. Signaling to consumers. The Evolus story has evolved since David Moatazedi became CEO last spring. Before Moatazedi took over, Evolus’ message primarily focused on the opportunity to compete on price. However, we think this message undersold the company’s product, since it implied Jeuveau, then known as DWP-450, was no different than other lower-cost BoNT-A products already on the market, Merz’s Xeomin." (4/4/2019) Has Evolus been receiving favorable news coverage? News coverage about EOLS stock has trended very negative this week, according to InfoTrie. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Evolus earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Evolus. Are investors shorting Evolus? Evolus saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,560,000 shares, an increase of 15.1% from the January 15th total of 5,700,000 shares. Based on an average daily volume of 638,300 shares, the short-interest ratio is presently 10.3 days. Currently, 29.4% of the shares of the company are sold short. View Evolus' Current Options Chain. Who are some of Evolus' key competitors? Some companies that are related to Evolus include Intra-Cellular Therapies (ITCI), Supernus Pharmaceuticals (SUPN), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Revance Therapeutics (RVNC), Phibro Animal Health (PAHC), Endonovo Therapeutics (ENDV), NextCure (NXTC), Portola Pharmaceuticals (PTLA), Myovant Sciences (MYOV), Opko Health (OPK), Akebia Therapeutics (AKBA), Enanta Pharmaceuticals (ENTA), Dermira (DERM) and ImmunoGen (IMGN). What other stocks do shareholders of Evolus own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include Celadon Group (CGI), Advanced Micro Devices (AMD), Revance Therapeutics (RVNC), Camtek (CAMT), Plug Power (PLUG), Micron Technology (MU), Tandem Diabetes Care (TNDM), Calithera Biosciences (CALA), JD.Com (JD) and Canopy Growth (CGC). Who are Evolus' key executives? Evolus' management team includes the folowing people: Mr. David Moatazedi, Pres, CEO & Director (Age 41)Ms. Lauren P. Silvernail, CFO & Exec. VP of Corp. Devel. (Age 60)Mr. Michael Mazen Jafar, Chief Marketing Officer (Age 38)Mr. Alejandro Sabad, VP of OperationsMr. Ashwin K. Agarwal, VP of Fin., Investor Relations & Treasury When did Evolus IPO? (EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities served as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers. Who are Evolus' major shareholders? Evolus' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Tang Capital Management LLC (7.88%), Cadian Capital Management LP (1.52%), Goldman Sachs Group Inc. (1.44%), State Street Corp (0.89%), Point72 Asset Management L.P. (0.62%) and Voss Capital LLC (0.28%). Company insiders that own Evolus stock include Bosun Hau, Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Michael M Jafar, Rui Avelar, Simone Blank and Vikram Malik. View Institutional Ownership Trends for Evolus. Which institutional investors are selling Evolus stock? EOLS stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Raymond James Financial Services Advisors Inc., Bank of America Corp DE, B. Riley Wealth Management Inc., Advisor Group Inc., Victory Capital Management Inc., Victory Capital Management Inc. and Janney Montgomery Scott LLC. Company insiders that have sold Evolus company stock in the last year include Corp Alphaeon, Lauren P Silvernail and Rui Avelar. View Insider Buying and Selling for Evolus. Which institutional investors are buying Evolus stock? EOLS stock was bought by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Goldman Sachs Group Inc., Point72 Asset Management L.P., Cadian Capital Management LP, Voss Capital LLC, State Street Corp, Bank of New York Mellon Corp and Virtu Financial LLC. Company insiders that have bought Evolus stock in the last two years include Bosun Hau, David N Gill, Kristine Romine, Michael M Jafar, Simone Blank and Vikram Malik. View Insider Buying and Selling for Evolus. How do I buy shares of Evolus? Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Evolus' stock price today? One share of EOLS stock can currently be purchased for approximately $9.69. How big of a company is Evolus? Evolus has a market capitalization of $323.84 million. The company earns $-46,870,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Evolus employs 70 workers across the globe.View Additional Information About Evolus. What is Evolus' official website? The official website for Evolus is http://www.evolus.com/. How can I contact Evolus? Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected] MarketBeat Community Rating for Evolus (NASDAQ EOLS)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 263 (Vote Outperform)Underperform Votes: 217 (Vote Underperform)Total Votes: 480MarketBeat's community ratings are surveys of what our community members think about Evolus and other stocks. Vote "Outperform" if you believe EOLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EOLS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/18/2020 by MarketBeat.com StaffFeatured Article: What are popular green investing opportunities?
